

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37945-0001

Applicant(s): Angus George DALGLEISH *et al.*

Serial No.: 09/857,691

Examiner: Unassigned

Filing Date: September 5, 2001

Group Art Unit: 1645

Title: USE OF HUMAN PROSTATE CELL LINES IN CANCER  
TREATMENT

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Applicants believe that the instant Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits under 37 CFR §1.97(b)(3), therefore, no fee is required in connection with its filing.




1645 IDS  
12/28/01  
NOV 06 2001  
TECH CENTER 1600/2900  
RECEIVED

U.S. Serial No. 09/857,691

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialled copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,



John P. Isacson  
Reg. No. 33,715

November 1, 2001

Date

HELLER EHRMAN WHITE & MCAULIFFE  
1666 K Street, N.W., Suite 300  
Washington, D.C. 20006  
Phone: (202) 912-2000  
Fax: (202) 912-2020



26633

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY DEFICIENCY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT NO. 08-1641.